Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS - PubMed (original) (raw)
Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS
G Sandström et al. FEMS Microbiol Immunol. 1992 Oct.
Abstract
Lipopolysaccharide (LPS) from the live vaccine strain of Francisella tularensis (F. tularensis LVS) was isolated and purified. The LPS did not stimulate lymphocytes from previously tularaemia-vaccinated individuals or lymphocytes from non-primed individuals. However, serum antibodies from tularaemia vaccinees reacted with the LPS whereas virtually no reactivity was found with antibodies from individuals not exposed to F. tularensis LVS. Antibodies of immunoglobulin class M displayed the antibody reactivity predominantly. The LPS failed to induce the mononuclear cell-derived cytokine interleukin-1 and only low levels of tumour necrosis factor were detected. Furthermore, no LPS endotoxin properties were found in galactosamine-treated mice or in the Limulus amoebocyte lysate assay. From these results it can be concluded that F. tularensis LVS possesses a lipopolysaccharide-like molecule, which does not exhibit properties of a classical endotoxin.
Similar articles
- Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
Dreisbach VC, Cowley S, Elkins KL. Dreisbach VC, et al. Infect Immun. 2000 Apr;68(4):1988-96. doi: 10.1128/IAI.68.4.1988-1996.2000. Infect Immun. 2000. PMID: 10722593 Free PMC article. - Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.
Kieffer TL, Cowley S, Nano FE, Elkins KL. Kieffer TL, et al. Microbes Infect. 2003 Apr;5(5):397-403. doi: 10.1016/s1286-4579(03)00052-2. Microbes Infect. 2003. PMID: 12737995 - Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.
Chiavolini D, Weir S, Murphy JR, Wetzler LM. Chiavolini D, et al. Clin Vaccine Immunol. 2008 Sep;15(9):1322-9. doi: 10.1128/CVI.00125-08. Epub 2008 Jul 9. Clin Vaccine Immunol. 2008. PMID: 18614668 Free PMC article. - Nature of protective immunity to Francisella tularensis.
Tärnvik A. Tärnvik A. Rev Infect Dis. 1989 May-Jun;11(3):440-51. Rev Infect Dis. 1989. PMID: 2665002 Review. - Cell-mediated immunity against Francisella tularensis after natural infection.
Koskela P, Herva E. Koskela P, et al. Scand J Infect Dis. 1980;12(4):281-7. doi: 10.3109/inf.1980.12.issue-4.08. Scand J Infect Dis. 1980. PMID: 7006062 Review.
Cited by
- Preparation of monoclonal antibodies for detection and identification of Francisella tularensis.
Hotta A, Uda A, Fujita O, Tanabayashi K, Yamada A. Hotta A, et al. Clin Vaccine Immunol. 2007 Jan;14(1):81-4. doi: 10.1128/CVI.00057-06. Epub 2006 Nov 22. Clin Vaccine Immunol. 2007. PMID: 17121981 Free PMC article. - A Francisella mutant in lipid A carbohydrate modification elicits protective immunity.
Kanistanon D, Hajjar AM, Pelletier MR, Gallagher LA, Kalhorn T, Shaffer SA, Goodlett DR, Rohmer L, Brittnacher MJ, Skerrett SJ, Ernst RK. Kanistanon D, et al. PLoS Pathog. 2008 Feb 8;4(2):e24. doi: 10.1371/journal.ppat.0040024. PLoS Pathog. 2008. PMID: 18266468 Free PMC article. - Structure and biosynthesis of free lipid A molecules that replace lipopolysaccharide in Francisella tularensis subsp. novicida.
Wang X, Ribeiro AA, Guan Z, McGrath SC, Cotter RJ, Raetz CR. Wang X, et al. Biochemistry. 2006 Dec 5;45(48):14427-40. doi: 10.1021/bi061767s. Biochemistry. 2006. PMID: 17128982 Free PMC article. - Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.
Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, Wilson CB, Hajjar AM, Skerrett SJ. Lembo A, et al. J Immunol. 2008 Jun 1;180(11):7574-81. doi: 10.4049/jimmunol.180.11.7574. J Immunol. 2008. PMID: 18490759 Free PMC article. - Cytokine expression in the liver during the early phase of murine tularemia.
Golovliov I, Sandström G, Ericsson M, Sjöstedt A, Tärnvik A. Golovliov I, et al. Infect Immun. 1995 Feb;63(2):534-8. doi: 10.1128/iai.63.2.534-538.1995. Infect Immun. 1995. PMID: 7822019 Free PMC article.